SOMNF (SomnoMed) YoY EBITDA Growth: -100.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SOMNF SomnoMed Ltd SOMNF
40 GF Score
Price $0.45
GF Value $0.55
! 3 Warning Signs
View Full Analysis

What is SomnoMed YoY EBITDA Growth?

SomnoMed SOMNF 40 YoY EBITDA Growth is -100.00% as of Jun. 2026. GuruFocus rates SOMNF with a GF Score™ of 40/100 and a GF Value™ of $0.55. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. SomnoMed's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -100.00%.

SomnoMed's EBITDA per Share for the six months ended in Jun. 2026 was $0.00.

SomnoMed YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for SomnoMed's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SomnoMed YoY EBITDA Growth Chart

SomnoMed Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -86.96 -33.33 -800.00 214.29 6.25

SomnoMed Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -500.00 333.33 112.50 14.29 -100.00
SOMNF
40GF Score
SomnoMed Ltd SOMNF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SomnoMed YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

SomnoMed's YoY EBITDA Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (A: Jun. 2026 )
=(EBITDA per Share (A: Jun. 2026 )-EBITDA per Share (A: Jun. 2025 ))/ | EBITDA per Share (A: Jun. 2025 ) |
=(0.017-0.016)/ | 0.016 |
=6.25 %

SomnoMed's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0-0.001)/ | 0.001 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -100.00% mean?
SomnoMed (SOMNF) has a YoY EBITDA Growth of -100.00% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for SomnoMed and its competitors.
Is SomnoMed's YoY EBITDA Growth too high?
SomnoMed's current YoY EBITDA Growth is -100.00%. Overall, SomnoMed has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's YoY EBITDA Growth compare to ABT and SYK?
SomnoMed's YoY EBITDA Growth of -100.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for SomnoMed and its competitors. SomnoMed's current YoY EBITDA Growth is -100.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
SomnoMed (SOMNF) has a current YoY EBITDA Growth of -100.00%. The stock's GF Value™ is $0.55, compared to a current price of $0.45 — trading 18.6% below its estimated fair value. The current YoY EBITDA Growth is -100.00%. SomnoMed's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For SomnoMed (SOMNF), the current YoY EBITDA Growth is -100.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SomnoMed (SOMNF) Overvalued in 2026?

Based on GuruFocus' analysis, SomnoMed stock appears to be undervalued. The current stock price of $0.45 is trading 18.6% below its estimated GF Value™ of $0.55.

Key valuation signals for SOMNF:

  • YoY EBITDA Growth: -100.00%
  • GF Value™: $0.55 vs. price of $0.45 (18.6% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the SOMNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SomnoMed Business Description

Other Exchanges RJV:GermanySOM:Australia
Address 20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
40GF Score

Get the complete analysis for SOMNF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price
$0.55
GF Value